TP53 and cancer: We recently found that NRF2 activation, by a novel ruthenium(II)–curcumin compound, plays a pro-survival role in both wild-type (wt) p53- and mutant (mut) p53-carrying cancer cells balancing cell death/survival; thus, inhibiting the NRF2 survival pathway could increase cancer cell death [12,13].